Could less protamine be safer for heart surgery patients?

NCT ID NCT07477977

Recruiting now Disease control Sponsor: Sohag University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving a lower dose of protamine (a drug that reverses the blood thinner heparin) after heart-lung bypass is safe and effective. About 195 adults having elective heart surgery will be randomly assigned to one of three protamine doses. The goal is to see if lower doses still work well while causing fewer side effects like bleeding or blood pressure problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: protamine sulfate
What this could lead to: If successful, this could lead to safer heart surgery with fewer side effects from protamine, like bleeding or unstable blood pressure.
What could go wrong: This is a small, early-phase trial, so results may not apply to all patients. Lower doses might not fully reverse heparin, raising bleeding risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPEN HEART SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Postoperative Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPEN HEART SURGERY

Contacts and locations

Locations

Sohag University Hospital
RECRUITING

Sohag, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.